Long non-coding RNA (lncRNA) DSCAM-AS1 is upregulated in breast cancer

2021 ◽  
pp. 1-6
Author(s):  
Mahsa Tarighi ◽  
Mohammad Khalaj-Kondori ◽  
Asghar Hosseinzadeh ◽  
Maryam Abtin
Keyword(s):  
Breast Cancer ◽  
Roc Curve ◽  
Noncoding Rna ◽  
Area Under The Curve ◽  
Clinicopathological Characteristics ◽  
Curve Analysis ◽  
Cancer Development ◽  
Roc Curve Analysis ◽  
Neoplastic Tissue ◽  
Tissue Samples

BACKGROUND: Accumulating evidence highlights that long noncoding RNA (lncRNA) DSCAM-AS1 play a key regulatory role in different stages of cancer development and progression. This study aimed to investigate whether the expression of DSCAM-AS1 is deregulated in breast cancer. MATERIALS AND METHODS: The relative expression of DSCAM-AS1 was measured in fifty breast cancerous and matched adjacent non-neoplastic tissue samples using quantitative real-time polymerase chain reaction (qPCR) technique. The association between DSCAM-AS1 expression and patients’ clinicopathological features was evaluated. Sensitivity and specificity of the DSCAM-AS1 expression for diagnosing breast cancer was obtained by the receiver operating characteristic (ROC) curve analysis. RESULTS: Our results showed that the expression of DSCAM-AS1 was significantly up-regulated in breast cancerous tissues compared with the matched adjacent non-neoplastic tissues (P < 0.05). Furthermore, we observed a significant association between the DSCAM-AS1 expression and lymph node metastasis (P = 0.011) but no other clinicopathological characteristics (P > 0.05). ROC curve analysis resulted in an area under the curve (AUC) of 0.67 and showed that the DSCAM-AS1 expression level may discriminate cancerous and non-cancerous tissues with 68% sensitivity and 76% specificity. CONCLUSION: This study provides further evidence that the expression of DSCAM-AS1 is deregulated in breast cancer and highlights its potential in breast cancer development.

Pretreatment 18F-FDG uptake heterogeneity predicts response to pyrotinib in patients with metastatic HER2-positive breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e15026-e15026
Author(s):  
Cc Gong ◽  
Cheng Liu ◽  
Zhonghua Tao ◽  
Jian Zhang ◽  
Leiping Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Roc Curve ◽  
Fdg Pet ◽  
Standardized Uptake Value ◽  
Curve Analysis ◽  
Roc Curve Analysis ◽  
Her2 Positive ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Positive Breast Cancer

e15026 Background: Heterogeneity of 18F-fluorodeoxyglucose (FDG) uptake is a promising marker for predicting response to treatment. This study aimed to evaluate the ability of pretreatment positron emission tomography/computed tomography (PET/CT) 18F-FDG-based heterogeneity to predict the response to pyrotinib in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC). Methods: Patients with MBC in the Fudan University Shanghai Cancer Center who underwent whole-body 18F-FDG PET/CT before the initiation of pyrotinib was included. The intertumoral and intratumoral heterogeneity indexes (HI-inter and HI-intra, respectively), maximum standardized uptake value (SUVmax), total lesion glycolysis (TLG), and metabolic tumor volume (MTV) on the baseline PET/CT were assessed. Progression-free survival (PFS) was estimated by the Kaplan-Meier method and compared by log-rank test. Time-dependent receiver operating characteristic (ROC) curve analysis was performed, and the predictive accuracies of all markers were evaluated by plotting the cumulative area under the ROC curve (AUC) over time. Results: A total of 22 patients were included in this study. The median PFS of patients with a high HI-intra (> 1.9) was 6.6 months, whereas that of patients with a low HI-intra was 13.4 months (p = 0.044). The HI-inter was able to discriminate patients as well as the coefficient of variance. Univariate analysis showed that patients with a higher HI-inter tended to have worse PFS (10.6 months vs. 13.4 months, p = 0.067). Higher SUVmax and TLG were also associated with worse PFS. ROC curve analysis confirmed the predictive value of the HI-inter and HI-intra. TLG had the highest accuracy in predicting PFS (AUC = 0.87), followed by HI-inter (AUC = 0.86), SUVmax (AUC = 0.85), HI-intra (AUC = 0.80), mean standardized uptake value (AUC = 0.63), and MTV (AUC = 0.60). Conclusions: Intratumoral and intertumoral heterogeneities in metastatic lesions on pretreatment 18F-FDG PET/CT could predict response to pyrotinib treatment in patients with HER2-positive breast cancer, which could provide information to guide treatment decisions.

scholarly journals Evaluation of serum AFP and DCP levels in the diagnosis of early-stage HBV-related HCC under different backgrounds

2020 ◽  
Vol 48 (10) ◽  
pp. 030006052096908
Author(s):  
Ting Song ◽  
Lili Wang ◽  
Ruopei Xin ◽  
Liping Zhang ◽  
Yun Tian
Keyword(s):  
Roc Curve ◽  
Diagnostic Performance ◽  
Operating Characteristic ◽  
Early Stage ◽  
Area Under The Curve ◽  
Curve Analysis ◽  
Roc Curve Analysis ◽  
Chronic Hbv Infection ◽  
B Virus ◽  
Chronic Hbv

Objective This study compared the diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxyprothrombin (DCP) in early-stage hepatitis B virus-related hepatocellular carcinoma (HBV-HCC) under different backgrounds. Methods Patients were enrolled and divided in four groups: chronic HBV infection (CHB), liver cirrhosis (LC), early-stage CHB-HCC, and early-stage LC-HCC. Serum AFP and DCP levels were measured. Receiver-operating characteristic (ROC) curve and area under the curve (AUC) analyses were applied to compare the diagnostic performance of DCP and AFP for HCC. Results In total, 200 patients were enrolled, including 48, 64, 33, and 55 patients with CHB, LC, CHB-HCC, and LC-HCC, respectively. ROC curve analysis revealed that the AUCs of AFP, DCP, and their combination in differentiating early-stage LC-HCC from LC were 0.776, 0.758, and 0.786, respectively. The values of these markers in discriminating early-stage CHB-HCC from CHB were 0.828, 0.731, and 0.862, respectively. Conclusions DCP was inferior to AFP in differentiating early-stage CHB-HCC from CHB. However, AFP and DCP displayed similar performance in distinguishing early-stage LC-HCC and LC.

scholarly journals Tumor-Educated Platelet miR-18a-3p as a Novel Liquid-Biopsy Biomarker for Early Diagnosis and Chemotherapy Efficacy Monitoring in Nasopharyngeal Carcinoma

2021 ◽  
Vol 11 ◽  
Author(s):  
Kaiyu Sun ◽  
Hui Wang ◽  
Xianqun Xu ◽  
Xiuqi Wei ◽  
Jingyu Su ◽  
...  
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Early Diagnosis ◽  
Roc Curve ◽  
Liquid Biopsy ◽  
Area Under The Curve ◽  
Curve Analysis ◽  
Clinical Value ◽  
Roc Curve Analysis ◽  
Expression Levels ◽  
Chemotherapy Efficacy

AimsTo evaluate the value of tumor-educated platelet (TEP) miR-18a-3p in the early diagnosis and chemotherapy efficacy monitoring of nasopharyngeal carcinoma (NPC).MethodsExpression levels of miR-18a-3p in platelets and plasma were detected by relative quantitative real-time PCR in NPC patients (n=54) and normal subjects (n=36). Diagnostic values of TEP miR-18a-3p for NPC was assessed by receiver operating characteristic (ROC) curve analysis. Follow up study was carried out to observe the dynamic changes of TEP miR-18a-3p with chemotherapy on 3 NPC patients.ResultsThe expression levels of TEP miR-18a-3p in NPC patients were significantly higher than that in healthy controls (p &lt; 0.0001). ROC curve analysis showed that the area under the curve (AUC) value was 0.841, the sensitivity and specificity for the diagnosis of NPC were 87% and 72.7%. No correlation was found between expression levels of TEP miR-18a-3p and patients’ clinical parameters and their NPC tumor-node-metastasis (TNM) stage. The positive rate of TEP miR-18a-3p and EBV DNA for NPC diagnosis were 85.4% and 66.7%. TEP miR-18a-3p expression were down-regulated after 77.8% (7 of 9) of chemotherapy, and in 66.7% (2 of 3) patients, TEP miR-18a-3p levels decreased after 3 cycles of chemotherapy.ConclusionThe expression levels of TEP miR-18a-3p are upregulated in NPC and have a high probability to downregulated after chemotherapy, indicating a significant clinical value. TEP miR-18a-3p might serve as a novel type of liquid-biopsy biomarker for early diagnosis and chemotherapy efficacy monitoring in NPC.

scholarly journals Risk Factors to Predict Ocular Metastasis in Older Adult Patients With Gastric Cancer:LDL, ApoA1, and CA724

2022 ◽  
Vol 21 ◽  
pp. 153303382110658
Author(s):  
Wen-Qing Shi ◽  
Shi-Nan Wu ◽  
Tie Sun ◽  
Hui-Ye Shu ◽  
Qi-Chen Yang ◽  
...  
Keyword(s):  
Risk Factors ◽  
Roc Curve ◽  
Area Under The Curve ◽  
Density Lipoprotein ◽  
Demographic Characteristics ◽  
Curve Analysis ◽  
Apolipoprotein A1 ◽  
Roc Curve Analysis ◽  
Significant Difference ◽  
Ocular Metastasis

Objective: The purpose of this study was to explore the risk factors for Ocular metastasis (OM) of Gastric cancer (GC). Methods: This is a retrospective cohort study. A total of 1165 patients with GC were enrolled in this study and divided into OM and non-ocular metastasis (NOM) groups. Chi-square and independent samples t tests were used to determine whether differences in demographic characteristics and serological indicators (SI) between the two groups were significant. In addition, binary logistic regression was used to analyze the value of various SI as risk factors for OM in patients with GC. The statistical threshold was set as P < .05. Finally, receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic value of various SI in differentiating the occurrence of OM in patients with GC. Results: The incidence of OM in older adults with GC was 1.1%. Adenocarcinoma was the most common type of GC in both groups, and there was no significant difference in demographic characteristics between the groups. Low-density lipoprotein (LDL), carbohydrate antigen-724 (CA724), and carcinoembryonic antigen levels were significantly higher in the OM group than the NOM group, while those of apolipoprotein A1 (ApoA1) were significantly lower in the OM than the NOM group. Binary logistic analysis showed that LDL, ApoA1, and CA724 were independent risk factors for OM in patients with GC ( P < .001, P = .033, and P = .008, respectively). ROC curve analysis generated area under the curve (AUC) values of 0.881, 0.576, and 0.906 for LDL, ApoA1, and CA724, respectively. In addition, combined analysis of LDL, ApoA1, and CA724 generated the highest AUC value of 0.924 ( P < .001). Conclusion: Among SI, LDL, ApoA1, and CA724 have predictive value for the occurrence of OM in GC, with the three factors combined having the highest value.

scholarly journals Diagnostic Performance of Cortactin in the Diagnosis of Oral Squamous Cell Carcinoma

2020 ◽  
Author(s):  
Lili Wang ◽  
Hongguang Song ◽  
Shiming Yang
Keyword(s):  
Squamous Cell Carcinoma ◽  
Oral Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Mrna Expression ◽  
Squamous Cell ◽  
Roc Curve ◽  
Area Under The Curve ◽  
Diagnostic Value ◽  
Curve Analysis ◽  
Roc Curve Analysis

Abstract Background: Cortactin gene was up-regulated in various human cancers. However, the role of cortactin in the diagnosis of oral squamous cell carcinoma (OSCC) remained unclear. The aim of this study was to investigate the diagnostic value of cortactin in OSCC patients.Methods: The relative mRNA expression levels of cortactin in OSCC tissues and adjacent normal oral mucosal tissues were detected by quantitative real-time polymerase chain reaction (qRT-PCR). Chi-square test was used to analyze the correlation between cortactin expression and clinical characteristics of patients. The diagnostic value of cortactin in OSCC patients was estimated via receiver operating characteristic (ROC) curve analysis.Results: Compared with the normal controls, cortactin mRNA expression was significantly increased in OSCC tissues (P<0.001). Importantly, notable correlations were found between cortactin expression and tumor size (P=0.040), TNM stage (P=0.018), lymph node metastasis (P=0.013) as well as recurrence (P=0.031). Furthermore, the result of ROC curve analysis showed that the area under the curve (AUC) was 0.867 with a sensitivity of 76.2% and a specificity of 86.9%. It revealed that the diagnostic value of cortactin was high in OSCC patients.Conclusions: Our data reveal that cortactin expression is up-regulated in OSCC and correlated with tumor progression. Cortactin may be a potential bio-marker for early diagnosis of OSCC.

scholarly journals An Adjunct Indicator for the Diagnosis of Fracture-Related Infections: Platelet Count to Mean Platelet Volume Ratio

2020 ◽  
Vol 5 (2) ◽  
pp. 54-59
Author(s):  
John Strony ◽  
Taylor Paziuk ◽  
Brianna Fram ◽  
Kyle Plusch ◽  
Gerard Chang ◽  
...  
Keyword(s):  
Platelet Count ◽  
Roc Curve ◽  
Mean Platelet Volume ◽  
Area Under The Curve ◽  
Volume Ratio ◽  
Curve Analysis ◽  
Platelet Volume ◽  
Roc Curve Analysis ◽  
Significant Difference ◽  
Fracture Nonunion

Abstract. Introduction: Fracture-related infection (FRI) is a common complication associated with orthopaedic fracture care. Diagnosing these complications in the preoperative setting is difficult. Platelets are a known acute phase reactant with indices that change in accordance with infection and inflammation. The purpose of our study was to assess the diagnostic utility of platelet indices at assessing FRI.Methods: A retrospective review performed for all patients who underwent revision surgery for fracture nonunion between 2013 and 2018. Radiographs were employed to define nonunion. Intraoperative cultures were used to define FRI. Receiver operator characteristic (ROC) curve analysis was used to assess the diagnostic ability of preoperative erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and the platelet count/mean platelet volume ratio (P/V) at recognizing FRI.Results: Of the 53 revision surgeries that were performed for fracture nonunion, 17 (32.1%) were identified as FRI. There were no significant demographic differences between the two cohorts. Patients with FRIs exhibited higher values for ESR (54.82 vs. 19.16, p<0.001), CRP (0.90 vs. 0.35, p=0.003), and P/V (37.4 vs. 22.8, p<0.001) as compared to those within the aseptic nonunion cohort. ROC curve analysis for P/V demonstrated that at an optimal ratio of 23, area under the curve (AUC) is 0.814, specificity is 55.6%, and sensitivity is 100.0%. There was no significant difference in the diagnostic performance of the serum biomarkers but only ESR and P/V had an AUC greater than 0.80. The negative predictive value (NPV) for P/V, ESR, and CRP was 100.0%, 84.6%, and 78.6%, respectively.Conclusion: The P/V ratio may serve as a reliable screening test for FRI.

scholarly journals Predicting Tissue HER2 Status Using Serum HER2 Levels in Patients with Metastatic Breast Cancer

2006 ◽  
Vol 52 (8) ◽  
pp. 1510-1515 ◽  
Author(s):  
Sun-Young Kong ◽  
Byung-Ho Nam ◽  
Keun Seok Lee ◽  
Youngmee Kwon ◽  
Eun Sook Lee ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Roc Curve ◽  
Direct Determination ◽  
Metastatic Breast ◽  
Curve Analysis ◽  
Optimal Decision ◽  
Her2 Status ◽  
Fish Analysis ◽  
Roc Curve Analysis

Abstract Background: Immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) are reliable ways to identify overexpression or amplification of the HER-2/neu (HER2, symbol ERBB2) gene, but each technique requires a high-quality tissue sample, which may not be available. We investigated whether serum concentrations of the HER2 extracellular domain (ECD) can be used as an alternative to tissue HER2 status in metastatic breast cancer, and we defined an optimal decision-level concentration of serum HER2 for prediction of tissue HER2 status. Methods: In 195 patients with metastatic breast cancer, we determined HER2 expression by IHC and performed FISH analysis on tumors for which IHC staining was graded as 2+. We measured serum HER2 by immunoassay and used ROC curve analysis to determine optimal serum HER2 ECD concentrations for differentiation between positive and negative HER2 status. Results: IHC results were 0/1+ for 30 (15%) of the patients, 2+ for 89 (46%), and 3+ for 76 (39%). FISH revealed HER2 amplification in 19 (21%) of the IHC 2+ tumors. Mean (SE) serum HER2 ECD was 22.2 (5.1) μg/L in the tissue HER2-negative group, significantly lower than the concentration of 363 (96) μg/L in the tissue HER2-positive group (P &lt;0.0001). ROC curve analysis showed 95% specificity and 62% sensitivity for tissue HER2 positivity at 37 μg/L of serum HER2. Conclusion: To use serum HER2 concentration as an alternative to direct determination of tissue HER2 status, we suggest 37 μg/L as a cutoff for predicting positive tissue HER2 with 95% specificity. Sensitivity, however, is low.

Role of Sialic Acid and Alkaline Dnase in Breast Cancer

1997 ◽  
Vol 12 (2) ◽  
pp. 61-67 ◽  
Author(s):  
G.N. Raval ◽  
L.J. Parekh ◽  
M.M. Patel ◽  
P.S. Patel ◽  
R.M. Rawal ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Sialic Acid ◽  
Cancer Patients ◽  
Roc Curve ◽  
Serum Levels ◽  
Curve Analysis ◽  
T Test ◽  
Breast Cancer Patients ◽  
Roc Curve Analysis ◽  
Anticancer Treatment

Serum levels of sialic acid and alkaline DNase (ADA) were analysed in 495 blood samples collected from 170 breast cancer patients before and during/after anticancer treatment. Fifty-six healthy females were included in the study to define the cutoff values. The markers were analysed by highly sensitive spectrophotometric methods. Statistical evaluation of the data was done using Student's ‘t’ test, paired ‘t’ test and ROC curve analysis. The total sialic acid (TSA), lipid bound sialic acid (LSA) and ADA in sera of untreated breast cancer patients were significantly higher than in controls. ROC curve analysis revealed TSA and LSA to be useful markers for diagnosis of breast cancer. Serum levels of TSA and LSA were significantly decreased in complete responders as compared to their pretreatment values. The pretreatment ADA values showed much individual variation. However, responders showed higher levels of ADA than untreated patients. In nonresponders the values of the biomarkers were comparable with pretreatment levels. The study suggested that TSA and LSA can be helpful in the diagnosis of breast cancer. All three markers can be used for assessment of response to anticancer treatment in breast cancer patients.

Abstract 12875: Serum Neutrophil Gelatinase-associated Lipocalin Has a Predictive Value for the Neurological Outcome of Post Cardiac Arrest Victims

Circulation ◽  
2015 ◽  
Vol 132 (suppl_3) ◽  
Author(s):  
Tadashi Kaneko ◽  
Motoki Fujita ◽  
Yasuaki Ogino ◽  
Hiroki Irie ◽  
Shinsuke Iwashita ◽  
...  
Keyword(s):  
Cardiac Arrest ◽  
Roc Curve ◽  
Predictive Value ◽  
Neurological Outcome ◽  
Neuron Specific Enolase ◽  
Area Under The Curve ◽  
Curve Analysis ◽  
Roc Curve Analysis ◽  
Significant Difference ◽  
Neutrophil Gelatinase

Introduction: Neutrophil gelatinase-associated lopocalin (NGAL) is well known as the biomarker of acute kidney injury. Currently, serum NGAL is reported as the biomarker which is associated with mortality and multiple organ dysfunction syndrome in septic patients. In this study, we measured serum NGAL in post cardiac arrest syndrome (PCAS) patients to investigate the predictive value of neurological outcome. Hypothesis: Serum NGAL is associated with favorable neurological outcome of PCAS patients. Methods: 43 cases of PCAS patients were measured serum NGAL on day 1 and 2, and serum neuron specific enolase (NSE) was also measured on day 2. Patients were divided into two group (group G: CPC 1-2 and group P: CPC 3-5, CPC: cerebral performance categories). Serum NGAL and NSE were compared between group G and P. Receiver operation characteristic (ROC) curve analysis were performed of both NGAL and NSE. Results: Group G (n = 20) and P (n = 23) were analyzed. Serum NGAL showed significant difference in day 2 (G: 282±116 ng/mL v.s. P: 299±87 ng/mL in day1: P = 0.609, G: 185±124 ng/mL v.s. P: 353±110 ng/mL in day 2: P<0.001). The ROC curve analysis showed area under the curve of NGAL in day 2 was 0.871, and the area of NSE in day2 showed 0.918. Conclusions: Serum NGAL in PCAS patients had the predictive value for neurological outcome which is comparable to serum NSE. (This study was supported by grants from Japanese Ministry of Health, Labour and Welfare: No. 25462824)

Sign in / Sign up

Export Citation Format

Share Document